© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
(Reuters) – The U.S. Food and Drug Administration approved the 8-mg dose of Regeneron (NASDAQ:) Pharmaceuticals’ eye disease drug Eylea, the company said in a statement on Friday.
